Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 in Relapsed/Refractory Myeloid Neoplasms
NCT04272957Phase 1Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- May 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ranosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Incidence of adverse events at 24 weeks and Maximum tolerated dosage (MTD) and/or recommended phase 2 dosage (RP2D) at 24 weeks. Status: unknown.
02
Drugs
ranosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04272957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272957.